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Summary
Background—Infections with vancomycin-resistant enterococci (VRE) are a growing concern 
in hospitals. The impact of vancomycin resistance in enterococcal urinary tract infection is not 
well-defined.
Aim—To describe the epidemiology of enterococcal bacteriuria in a hospital and compare the 
clinical picture and patient outcomes depending on vancomycin resistance.
Methods—This was a 6-month prospective cohort study of hospital patients who were admitted 
with or who developed enterococcal bacteriuria in a 1250-bed tertiary care hospital. We examined 
clinical presentation, diagnostic work-up, management, and outcomes.
Findings—We included 254 patients with enterococcal bacteriuria; 160 (63%) were female and 
median age was 65 years (range: 17–96). A total of 116 (46%) bacteriurias were hospital-acquired 
and 145 (57%) catheter-associated. Most patients presented with asymptomatic bacteriuria (ASB) 
(119;47%) or pyelonephritis (64; 25%); 51 (20%) had unclassifiable bacteriuria and 20 (8%) had 
cystitis. Secondary bloodstream infection was detected in 8 (3%) patients. Seventy of 119 (59%) 
with ASB received antibiotics (mostly vancomycin). There were 74 (29%) VRE bacteriurias. VRE 
and vancomycin-susceptible enterococci (VSE) produced similar rates of pyelonephritis [19 (25%) 
vs 45 (25%); P = 0.2], cystitis, and ASB. Outcomes such as ICU transfer [10 (14%) VRE vs 17 
(9%) VSE; P = 0.3], hospital length of stay (6.8 vs 5.0 days; P = 0.08), and mortality [10 (14%) vs 
13 (7%); P = 0.1] did not vary with vancomycin susceptibility.
⋆This study was presented at IDweek 2012 in San Diego, California, USA (abstract #725).
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Conclusions—Vancomycin resistance did not affect the clinical presentation nor did it impact 
patient outcomes in this cohort of inpatients with enterococcal bacteriuria. Almost half of our 
cohort had enterococcal ASB; more than 50% of these asymptomatic patients received 
unnecessary antibiotics. Antimicrobial stewardship efforts should address overtreatment of 
enterococcal bacteriurias.
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Introduction
Enterococci are the third most frequent cause of urinary tract infections in hospitalized 
patients.1 These bacteria have been associated with cystitis, pyelonephritis, catheter-
associated urinary tract infections (UTIs) and asymptomatic bacteriuria, a condition which 
generally does not require antimicrobial treatment. There are limited data on the optimal 
treatment of symptomatic enterococcal UTI. Various antibiotics have been used, from low-
cost agents, such as amoxicillin and nitrofurantoin, to expensive drugs such as linezolid and 
daptomycin.2
Over the past two decades vancomycin-resistant enterococci (VRE) have become a common 
nosocomial pathogen. About 17% of all enterococcal isolates in the USA are vancomycin 
resistant and are primarily Enterococcus faecium and E. faecalis.3 VRE is perceived as a 
difficult-to-treat pathogen. It has been hypothesized that E. faecium maintains vancomycin 
resistance at the expense of being less virulent than E. faecalis.4 However, studies have 
reported that VRE bacteraemia results in poorer outcomes than vancomycin-susceptible 
enterococci (VSE) bacteraemias.5,6 Because vancomycin is a frequent empiric treatment in 
patients with sepsis of unclear aetiology, appropriate treatment of VRE bacteraemia may be 
delayed and result in worse patient outcomes. It is unclear whether this scenario is also true 
for UTIs, where vancomycin is not a typical empiric treatment.
Very few studies have scrutinized enterococcal UTIs in the age of widespread vancomycin 
resistance.7–10 In this study, we describe the clinical presentation, management, and 
outcomes of enterococcal bacteriuria in a tertiary care hospital in the midwestern USA. Our 
goals were: (i) to determine the frequency of enterococcal symptomatic UTIs and 
asymptomatic bacteriuria; (ii) to determine how often enterococcal asymptomatic bacteriuria 
is treated; (iii) to identify the antibiotics most commonly used in treatment; and (iv) to 
determine how management and outcomes vary between VRE and VSE bacteriuria.
Methods
Study design and setting
We conducted a prospective cohort study of patients with enterococcal bacteriuria admitted 
to Barnes–Jewish Hospital (BJH) between 1 July 2011 and 31 December 2011. BJH, a 
1250-bed teaching hospital, is the largest hospital in Missouri, and has a referral base that 
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includes the St Louis metropolitan area, eastern Missouri and western Illinois. It houses all 
medical specialties. BJH is affiliated with Washington University School of Medicine.
Inclusion and exclusion criteria
Patients with enterococcal bacteriuria were identified by means of a daily query of the 
hospital medical informatics system by one of the authors (H.K.). We included all adult 
inpatients with enterococcal bacteriuria (aged ≥17 years) and excluded outpatients or 
patients discharged home directly from the emergency department and those with concurrent 
non-enterococcal bacteraemia within 3 days of enterococcal bacteriuria. Polymicrobial 
bacteriurias were not excluded; they were defined as detection of two or more microbial 
species in the same urine culture.
Clinical data collection and laboratory work-up
Upon inclusion, one of the authors (H.K.) reviewed the patients' medical records to identify 
signs and symptoms associated with the bacteriuria. Demographic and clinical data were 
also collected plus pertinent laboratory and radiological findings. Both antibiotic 
management (including antibiotic prescriptions upon discharge) and urinary catheter 
management were recorded. Enrolled patients' medical records were reviewed daily during 
admission and the following outcomes were evaluated: (i) symptom resolution within 3 days 
of the start of treatment (or at the time of discharge if discharged within 3 days of the 
positive culture); (ii) secondary bloodstream infection; (iii) length of hospital stay; (iv) 
transfer to the intensive care unit (ICU); and (v) crude in-hospital mortality. Post-discharge 
outcomes of interest were readmission to the hospital within 30 days with recurrent 
bacteriuria and/or bacteraemia.
Routine microbiological work-up on the specimens was performed by the BJH Clinical 
Microbiology Laboratory, including speciation (into E. faecalis, E. faecium, or other 
enterococcal species) and testing for antimicrobial susceptibilities. The latter was done with 
disc diffusion methodology, using cut-offs proposed by the Clinical and Laboratory 
Standards Institute (http://www.clsi.org). The cut-off for significant bacteriuria employed in 
our hospital microbiology laboratory was 5 × 104 colony-forming units (CFU)/mL in non-
catheterized and 5 × 103 CFU in catheterized patients.
Definitions
Symptomatic UTI was defined as the presence of bacteriuria and one or more bladder 
symptoms (dysuria, hesitancy, frequency, suprapubic pain), flank pain and/or fever. Cystitis 
was defined as the presence of bladder symptoms, including dysuria, hesitancy, frequency, 
and suprapubic pain. Pyelonephritis was defined as the presence of fever and/or flank pain in 
a bacteriuric patient. Asymptomatic bacteriuria (ASB) denoted the absence of any of the 
above-mentioned symptoms.11 Patients unable to report symptoms were considered 
unclassifiable. Bacteriuria was considered to be catheter-associated if a urinary catheter was 
present within 48 h before the positive urine culture. Pyuria was defined as >10 white blood 
cells per high-power field in urine microscopy.
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In 2010, 28% of enterococci recovered from clinical urine cultures at BJH were vancomycin 
resistant. We hypothesized that a 15% difference in successful clinical treatment (i.e. 
resolution of symptoms at day 3 or at discharge) between VRE and VSE would be clinically 
significant. Assuming that symptom resolution is achieved in 80% of VRE bacteriurias vs 
95% of VSE bacteriurias it was estimated that 55 vs 141 patients (or total, 196) would be 
required to make a statistically significant statement (given alpha = 0.05 and power = 80%).
Statistical analysis
We used the statistical package SPSS (SPSS Inc., version 18, Chicago, IL, USA) to perform 
analyses. Univariate analyses included chi-square test or Fisher's exact test for categorical 
variables, as appropriate, and Student's t-test or Mann–Whitney U-test for continuous 
variables, as appropriate. P < 0.05 was considered statistically significant. Variables with P 
≤ 0.1 were included in a multivariate model. Outcomes were compared between VRE and 
VSE bacteriurias by means of the chi-square test. The project was approved by the Human 
Research Protection Office at Washington University (which waived informed consent due 
to the observational nature of the study) on 25 May 2011. The submission number was 
201104218.
Results
Epidemiology of enterococcal bacteriuria in hospitalized patients
In all, 254 patients with enterococcal bacteriuria were enrolled, of whom 160 (63%) were 
female and 171 (67%) white. The median age was 65 years (range: 17–96 years). The body 
mass index (BMI) was 26.3 kg/m2 (range: 15.7–79.6). The clinical manifestations ranged 
from ASB (119; 47%), to pyelonephritis (64; 25%), cystitis (20; 8%), and unclassified 
bacteriuria (51; 20%); 116 (46%) had hospital-acquired bacteriurias, and 145 (57%) were 
catheter-associated bacteriurias. Table I summarizes the baseline demographic 
characteristics and comorbidities of these patients, depending on vancomycin susceptibility. 
Seventy-four (29%) urine isolates were vancomycin resistant (VRE). Compared to those 
with VSE bacteriuria, patients with VRE bacteriuria were more likely to be non-white (P = 
0.02), to have renal insufficiency (P = 0.001), and to be receiving immunosuppressive 
treatment (corticosteroids, other immunosuppressants, chemotherapy). In multivariate 
analysis, non-white race [odds ratio (OR): 1.96; 95% confidence interval (CI): 1.05–3.70] 
and renal insufficiency (OR: 2.37; 95% CI: 1.27–4.41) were independent predictors of 
vancomycin resistance. Otherwise the two groups were similar in their demographics and 
comorbidities. A total of 177 (70%) patients received pathogen-directed antibiotic treatment.
Out of 254 isolates, 243 were available for speciation (96%). The majority of these were E. 
faecalis (176; 69%), followed by E. faecium (62; 24%), and other Enterococci spp. (5; 2%). 
E. faecalis were resistant to vancomycin in 32% of cases, whereas 79% of E. faecium were 
VRE. There were 61 (24%) polymicrobial bacteriurias. Polymicrobial bacteriurias were 
associated with functional or anatomical urinary tract abnormality (P = 0.01) and with 
pyuria (P = 0.03), but did not result in worse outcomes than monomicrobial infections (data 
not shown).
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Asymptomatic bacteriuria with enterococci
A significant number of patients had ASB (119; 47%), of which 70 (59%) received 
antibiotic treatment. Of the 70 who received antibiotic treatment, 24 (34%) had a 
concomitant diagnosis of infection at another site that could have led to antibiotic usage. 
Based on the medical record, we could not determine whether antibiotics were given to treat 
the bacteriuria or for the alternative indication in these patients; 46 (39%) of 119 ASB 
patients received antibiotics exclusively for ASB. The presence of pyuria in patients with 
ASB did not affect the likelihood of antibiotic administration [35/54 (65%) with pyuria vs 
33/65 (51%) without pyuria; P = 0.1]. Among antibiotics used for ASB, vancomycin (14/70; 
20%), ampicillin, and linezolid (each 13/70; 19%) were the most common. Vancomycin 
resistance was not associated with increased antibiotic use in ASB [15/28 (54%) in VRE vs 
55/91 (60%) in VSE; P = 0.5].
Impact of vancomycin resistance on clinical presentation
Of the 254 urine isolates tested, 74 (29%) were VRE. Overall, symptoms were not 
significantly more likely to be reported in VRE vs VSE infections [46/137 (34%) vs 28/121 
(24%); P = 0.06]. The two groups were also similar with regard to the subsets of cystitis, 
pyelonephritis, and ASB (Table II).
Management of enterococcal bacteriuria and patient outcomes
Out of 254 patients, 177 (70%) received pathogen-directed antibiotics. Linezolid was more 
likely to be used as the first pathogen-directed antibiotic in patients with VRE bacteriuria 
[25 (51%) vs 9 (7%) in VSE bacteriuria patients; P < 0.001]. Also, doxycycline [7 (14%) vs 
5 (4%); P = 0.02] and daptomycin [4 (8%) vs 0 (0%); P = 0.005] were more commonly used 
in patients with VRE infection. Twenty-four (32%) of VRE isolates were ampicillin 
susceptible; 7 (29%) were treated with linezolid. There were no significant differences in 
other antibiotics used. As expected, vancomycin was not used as pathogen-directed 
antibiotic for VRE. In addition to antibiotic management, catheter management was 
examined across the two groups: in the VRE group, 23 (55%) patients had catheters 
removed compared to 47 (45%) in the VSE group (P = 0.3).
Vancomycin susceptibility did not significantly alter outcomes such as transfer to ICU [10 
(14%) VRE vs 17 (9%) VSE; P = 0.3], length of hospital stay [6.8 days (0.1–150.8) vs 5 
days (0.2–78.2); P = 0.08], and mortality [10 (14%) vs 13 (7%); P = 0.1] (Table II). 
Outcomes were similarly unaffected in the symptomatic subset of patients (data not shown). 
Bacteraemia was present in 8 (3%) of the bacteriuria cases. Thirty-day post-discharge 
outcomes were similar independent of vancomycin resistance.
Discussion
Although enterococcus is the third-most frequent cause of UTI, its optimal treatment is 
poorly characterized. In addition, treatment has been complicated by widespread 
vancomycin resistance. In this prospective study of enterococcal bacteriuria at a tertiary care 
hospital, asymptomatic enterococcal bacteriuria was detected as frequently as symptomatic 
UTI, antibiotic therapy for asymptomatic enterococcal bacteriuria was frequently used, and 
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clinical severity was unaffected by enterococcal vancomycin resistance. Patient outcomes 
did not differ between those with VRE and VSE bacteriuria.
National guidelines state that ASB is, with very few exceptions, not an indication for 
antibiotic treatment.12 In spite of this, it is not uncommon for asymptomatic patients with 
positive urine cultures to receive antibiotics.13 A recent retrospective analysis of 
enterococcal bacteriurias in inpatients and outpatients at two centres serving veteran and 
immunocompromised populations, respectively, reported that approximately one-third of 
asymptomatic bacteriuric patients were treated with antibiotics.9 However, the authors did 
not report alternative indications for antibiotics. In this study of general hospital patients, we 
found that 59% of our patients with ASB received treatment. Even after accounting for 
possible alternative indications for treatment, 39% still received unnecessary antibiotics. We 
focused on hospitalized patients in our investigation for a number of reasons: (i) the 
complexity of patients seen in an urban, tertiary care hospital, and its impact on treatment 
decisions; (ii) the importance of antibiotic overtreatment of bacteriuria for antimicrobial 
stewardship; and (iii) the ability to follow outcomes prospectively during hospitalization. 
We feel that the lack of guidance on optimal treatment strategies may make enterococcal 
bacteriuria an ideal target for antimicrobial stewardship measures.
Clinical experience with enterococcal bloodstream infections would suggest that 
vancomycin resistance in enterococcal bacteriuria might be associated with worse 
outcomes.5,6 In this study we therefore compared the clinical manifestations between VRE 
and VSE bacteriurias. The frequencies of patients presenting with either cystitis or 
pyelonephritis were similar across the two groups. The fact that no difference was observed 
could be due to similar virulence in the two groups. Because VRE was more commonly 
encountered in patients with either immunosuppression or renal insufficiency, an alternative 
explanation might be that less virulent, vancomycin-resistant, enterococci are still able to 
cause significant clinical disease in vulnerable patients.14 African-American race was one of 
the independent predictors of VRE bacteriuria; this association has been reported 
previously.15 Renal insufficiency, the other predictor, may be a marker for increased 
healthcare exposure.16
No difference was found in outcomes between VRE and VSE bacteriuria. VRE bacteriurias 
were more frequently treated with newer agents with extended activity against Gram-
positive bacteria such as linezolid or daptomycin (overtreatment with these drugs has 
recently been described in a retrospective study focusing on VRE bacteriurias).10 The fact 
that we did not see worse outcomes in VRE infections may be due to greater clinical 
effectiveness of these newer antibiotics. Specifically, the role of linezolid in treating 
enterococcal bacteriuria is unresolved, although it is often an option of last resort for VRE. 
Alternatively, enterococcal bacteriuria may be a comparatively indolent entity with a low 
rate of complications regardless of antibiotic administration.17 Comparative effectiveness 
studies are needed to best define the treatment for enterococcal bacteriurias.
This study has limitations. Information on the patients' symptoms was collected from the 
medical records, not by patient interview by the investigators; it is possible that urinary 
symptoms were underreported by treating physicians. The study focused on hospitalized 
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patients in a tertiary centre, with many patients having complex comorbidities and 
occasionally concurrent indications for antibiotic use. Many patients were unable to report 
symptoms for different reasons (e.g. intubation, coma, psychiatric illness); these patients 
were analysed as a separate group (i.e. unclassifiable bacteriuria).
In conclusion, it was found that vancomycin resistance did not have a major impact on the 
clinical presentation and outcomes of enterococcal bacteriuria. This has not been examined 
before and is in stark contrast to studies on vancomycin resistance in bloodstream infections. 
The management of VRE bacteriuria was characterized by increased use of broad spectrum 
antibiotics – even among ampicillin-susceptible strains – and by a substantial proportion of 
patients treated for asymptomatic bacteriuria. These findings reinforce the need for 
antimicrobial stewardship in bacteriuria management.
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Table I
Baseline demographic data and comorbidities for 254 patients with enterococcal 








Age 67 (17–94) 74 (22–96) 0.9
Female 114 (63%) 46 (62%) 0.9
Body mass index (kg/m2, range) 26.5 (15.7–67.8) 26.0 (16.7–79.6) 0.1
White race 129 (72%) 42 (57%) 0.02
Catheter-associated bacteriuria 103 (57%) 42 (57%) 1.0
Hospital-acquired infection 80 (44%) 36 (49%) 0.5
Malignancy 59 (33%) 27 (37%) 0.6
Chemotherapy (past 30 days) 7 (4%) 8 (11%) 0.04
Diabetes mellitus 49 (27%) 21 (28%) 0.9
Immunosuppression 19 (11%) 16 (22%) 0.02
Steroids 28 (16%) 20 (27%) 0.03
HIV/AIDS 4 (2%) 1 (1%) 0.7
Any transplant 18 (10%) 12 (16%) 0.2
Serum creatinine >1.5 mg/dL 43 (24%) 33 (45%) 0.001
Cerebrovascular insult 37 (21%) 13 (18%) 0.6
Dementia 14 (8%) 5 (7%) 0.8
Hemiplegia/paraplegia and quadriplegia 16 (9%) 8 (11%) 0.6
Pyuria (WBC >10) 92 (55%) 39 (54%) 0.9
Functional or anatomical urinary 38 (21%) 16 (22%) 0.9
tract abnormality
Urological procedure prior to 13 (7%) 11 (15%) 0.06
UTI (this admission)
Previous urological procedure 41 (23%) 23 (31%) 0.2
Previous enterococcal UTI 29 (16%) 19 (26%) 0.08
HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; WBC, white blood cell count; UTI, urinary tract infection.













Khair et al. Page 10
Table II
Clinical presentation and patient outcomes in 254 episodes of enterococcal bacteriuria, 
depending on vancomycin susceptibility








 Cystitis 11 (6%) 9 (12%) 0.1
 Pyelonephritis 45 (25%) 19 (25%) 0.2
 Unclassified bacteriuria 33 (18%) 18 (24%) 0.3
 Asymptomatic bacteriuria 91 (51%) 28 (38%) 0.07
Patient outcomes
 Improvement of symptoms (documented) 47 (26%) 20 (27%) 0.9
 ICU transfer 17 (9%) 10 (14%) 0.3
 Length of stay after bacteriuria (days) 5.0 (0.2–78.2) 6.8 (0.1–150.8) 0.08
 Hospital all-cause mortality 13 (7%) 10 (14%) 0.1
 Enterococcal bacteraemia (in the first 3 days after bacteriuria) 5 (3%) 3 (4%) 0.7
 Enterococcal bacteraemia within 3–30 days after initial bacteriuria 3 (2%) 4 (6%) 0.1
 Hospital readmission within 30 days from discharge 46 (26%) 22 (30%) 0.5
 Recurrence of enterococcal bacteriuria within 3–30 days of initial culture 9 (5%) 4 (6%) 0.9
ICU, intensive care unit.
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